ciprofloxacin has been researched along with Prostatic Hyperplasia in 9 studies
Ciprofloxacin: A broad-spectrum antimicrobial carboxyfluoroquinoline.
ciprofloxacin : A quinolone that is quinolin-4(1H)-one bearing cyclopropyl, carboxylic acid, fluoro and piperazin-1-yl substituents at positions 1, 3, 6 and 7, respectively.
Prostatic Hyperplasia: Increase in constituent cells in the PROSTATE, leading to enlargement of the organ (hypertrophy) and adverse impact on the lower urinary tract function. This can be caused by increased rate of cell proliferation, reduced rate of cell death, or both.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h." | 5.27 | In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988) |
| "Ofloxacin has the advantage against ciprofloxacin of exceeding the MICs for Staphylococcus and Chlamydia." | 1.30 | A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion. ( Cheng, C; Foo, KT; Li, MK; Png, JC; Rekhraj, IR; Tan, E, 1997) |
| "Forty-four patients with benign prostatic hypertrophy treated with transurethral resection of the prostate were entered in this study." | 1.28 | [Ciprofloxacin concentration in human prostatic tissue following 3 days' administration]. ( Morita, M; Nakagawa, H; Suzuki, K, 1991) |
| "Fleroxacin is a new fluoroquinolone with a broad antibacterial spectrum and a serum half-life of about 8-12 h." | 1.27 | In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue. ( Grobecker, H; Kees, F; Metz, R; Naber, KG; Schumacher, H; Sörgel, F, 1988) |
| "The drug levels in prostatic adenoma tissue were similar to the concomitantly measured plasma levels." | 1.27 | Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue. ( Grobecker, H; Kees, F; Naber, KG; Schumacher, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (33.33) | 18.7374 |
| 1990's | 3 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 3 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Elshal, AM | 1 |
| Atwa, AM | 1 |
| El-Nahas, AR | 1 |
| El-Ghar, MA | 1 |
| Gaber, A | 1 |
| Elsawy, E | 1 |
| Hashem, A | 1 |
| Farag, Y | 1 |
| Farg, H | 1 |
| Elsorougy, A | 1 |
| Fouda, M | 1 |
| Nabeeh, H | 1 |
| Mosbah, A | 1 |
| Jichlinski, P | 1 |
| Santucci, R | 1 |
| Bouayad-Agha, K | 1 |
| Maloisel, F | 1 |
| Couturier, F | 1 |
| Png, JC | 1 |
| Tan, E | 1 |
| Foo, KT | 1 |
| Li, MK | 1 |
| Cheng, C | 1 |
| Rekhraj, IR | 1 |
| Tuhkanen, K | 1 |
| Heino, A | 1 |
| Ala-Opas, M | 1 |
| Morita, M | 1 |
| Nakagawa, H | 1 |
| Suzuki, K | 1 |
| Grabe, M | 1 |
| Forsgren, A | 1 |
| Björk, T | 1 |
| Naber, KG | 2 |
| Sörgel, F | 1 |
| Kees, F | 2 |
| Schumacher, H | 2 |
| Metz, R | 1 |
| Grobecker, H | 2 |
2 trials available for ciprofloxacin and Prostatic Hyperplasia
| Article | Year |
|---|---|
Chemoprophylaxis during transrectal prostate needle biopsy: critical analysis through randomized clinical trial.
Topics: Adenocarcinoma; Aged; Anti-Bacterial Agents; Antibiotic Prophylaxis; Biopsy, Large-Core Needle; Bloo | 2018 |
Contact laser prostatectomy compared to TURP in prostatic hyperplasia smaller than 40 ml. Six-month follow-up with complex urodynamic assessment.
Topics: Aged; Anti-Infective Agents; Ciprofloxacin; Follow-Up Studies; Humans; Laser Therapy; Male; Middle A | 1999 |
7 other studies available for ciprofloxacin and Prostatic Hyperplasia
| Article | Year |
|---|---|
[Urology in 2011].
Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Anti-Bacterial Agents; Anti-Infective Ag | 2012 |
[Ciprofloxacin-induced thrombopenia].
Topics: Anti-Bacterial Agents; Ciprofloxacin; Humans; Male; Middle Aged; Platelet Count; Prostatic Hyperplas | 2012 |
A comparative study of the distribution of ofloxacin and ciprofloxacin in prostatic tissues after simultaneous oral ingestion.
Topics: Administration, Oral; Anti-Infective Agents; Anti-Infective Agents, Urinary; Chromatography, High Pr | 1997 |
[Ciprofloxacin concentration in human prostatic tissue following 3 days' administration].
Topics: Administration, Oral; Aged; Aged, 80 and over; Ciprofloxacin; Humans; Male; Middle Aged; Premedicati | 1991 |
Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection.
Topics: Administration, Oral; Aged; Anti-Infective Agents; Ciprofloxacin; Humans; Male; Postoperative Compli | 1986 |
In-vitro activity of fleroxacin against isolates causing complicated urinary tract infections and concentrations in seminal and prostatic fluid and in prostatic adenoma tissue.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Body Fluids; Ciprofloxacin; Fleroxacin; Gram- | 1988 |
Penetration of fleroxacin into prostatic secretion and prostatic adenoma tissue.
Topics: Administration, Oral; Aged; Chromatography, High Pressure Liquid; Ciprofloxacin; Fleroxacin; Humans; | 1988 |